KRas G12C inhibitors for cancer treatment
Summary
The USPTO granted patent US12590105B2 to Eli Lilly and Company on March 31, 2026, covering 24 claims for KRas G12C inhibitors and their use in treating cancer. The patent, with application number 18255713 filed on November 24, 2021, protects specific compound formulations and methods of treatment. This grant provides Eli Lilly with enforceable intellectual property rights in the United States.
What changed
The USPTO issued patent grant US12590105B2 to Eli Lilly and Company for KRas G12C inhibitor compounds and methods of using these compounds for cancer treatment. The patent contains 24 claims covering specific molecular structures (formula R1-R5, A, B) and therapeutic applications. Inventors include David Michael Hyman, Gregory Lawrence Lackner, Sheng-Bin Peng, Bree Leigh Richey, and Chong Si.
Pharmaceutical companies and researchers developing KRas G12C targeted therapies should design around these patent claims or seek licensing arrangements with Eli Lilly. The patent provides 20-year exclusivity from the 2021 filing date, expiring in 2041. Freedom-to-operate analyses for cancer drug development programs should incorporate this granted patent.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
KRas G12C inhibitors
Grant US12590105B2 Kind: B2 Mar 31, 2026
Assignee
ELI LILLY AND COMPANY
Inventors
David Michael Hyman, Gregory Lawrence Lackner, Sheng-Bin Peng, Bree Leigh Richey, Chong Si
Abstract
The present disclosure provides compounds of the formula:
where R1, R2, R3, R4, R5, A, and B are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
CPC Classifications
C07D 498/04 A61K 45/06
Filing Date
2021-11-24
Application No.
18255713
Claims
24
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.